Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

Aethlon Medical receives Ethics Committee approval for Hemopurifier cancer trial in India: San Diego Saturday, September 21, 2024, 09:00 Hrs [IST] Aethlon Inc., a medical therapeu ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...